View

The Study

Comparative neurofilament light chain trajectories in CSF and plasma in autosomal dominant Alzheimer’s disease

In simple terms

This study watched people with a rare inherited form of Alzheimer’s for many years and saw that a protein in their blood and spinal fluid changed as their brain got worse. It doesn’t prove the protein causes the damage — it just shows they happen together.

66%

Analysis score

66/ 72

Maximum 72 for a cohort study.

Where the score came from

Reporting40
Methodology55
Publication100
Statistical77
Study type (basis of the score)
Cohort Study
Level 2b - Individual cohort study
What’s the bottom line?

Scientists tracked a protein in blood and spinal fluid that leaks out when brain cells die. They found it rises years before people feel symptoms of Alzheimer’s.

Where does this study sit?

Reviews of RCTs (Meta-analyses)

Max 100

Randomized Trials

Max 90

Reviews of Cohort Studies

Max 85

Cohort Studies

Max 72

Reviews of Case-Control Studies

Max 63

Case-Control Studies

Max 58

Cross-Sectional & Case Series

Max 50

Expert Opinion

Max 5
StrongerWeaker
Cohort Studies
Level 2b
66

66 / 100

Quality score

Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.

Cannot establish causation

Save studies & get personalized insights

Create a free account to save this study, track new evidence as it comes in, and get breakdowns of studies in the topics you care about.

Key takeaways

Summary

Based on the study abstract and findings.

  1. 1This means a simple blood test can warn of Alzheimer’s very early, but once symptoms appear, spinal fluid gives a more accurate picture of how fast the brain is deteriorating.
  2. 2The protein rises 18.9 years before symptoms in blood, and 24.6 years before in spinal fluid.
  3. 3After symptoms start, spinal fluid levels keep rising, but blood levels stop going up.

Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data

Publication

Journal

Nature Communications

Year

2024

Authors

Anna Hofmann, Lisa M. Häsler, Marius Lambert, S. Kaeser, Susanne Gräber‐Sultan, Ulrike Obermüller, Elke Kuder-Buletta, C. la Fougère, C. Laske, Jonathan Vöglein, J. Levin, Nick C. Fox, Natalie S. Ryan, H. Zetterberg, J. Llibre-Guerra, Richard J. Perrin, L. Ibanez, Peter R. Schofield, W. Brooks, Gregg S. Day, Martin R. Farlow, R. Allegri, P. Chrem Mendez, Takeshi Ikeuchi, K. Kasuga, Jae-Hong Lee, J. Roh, Hiroshi Mori, Francisco Lopera, Randall J. Bateman, E. McDade, B. Gordon, J. Chhatwal, Mathias Jucker, Stephanie A. Schultz, David Andrew J. Bryce Nicolas Randall Jacob A. Tammie Sa Aguillon Aschenbrenner Baker Barthelemy Bateman Be, D. Aguillón, A. Aschenbrenner, Bryce Baker, N. Barthélemy, Randall J. Bateman, Jacob Bechara, T. Benzinger, S. Berman, David M. Cash, Allison Chen, Charles D. Chen, Jasmeer P. Chhatwal Chhatwal, Patricio Chrem Mendez, L. Courtney, C. Cruchaga, Alisha J. Daniels, Gregg S. Day, Anne M. Fagan, Martin R. Farlow, Shaney Flores, E. Franklin, A. Goate, Susanne Graber-Sultan, N. Graff-Radford, Emily Gremminger, Jason J Hassenstab, Elizabeth M. Herries, David M. Holtzman, Russ C. Hornbeck, E. Huey, S. Ikonomovic, Kelley Jackson, Steve Jarman, Gina Jerome, E. Johnson, N. Joseph-Mathurin, Celeste M. Karch, S. Keefe, Deborah Koudelis, Y. Leon, A. Levey, Yan Li, Ruijin Lu, Jacob A. Marsh, Ralph N. Martins, Parinaz Massoumzadeh, C. Masters, Austin McCullough, Nicole S Mckay, Matthew Minton, John C. Morris, N. Nadkarni, J. Nicklaus, Yoshiki Niimi, James M Noble, Ulrike Obermueller, Danielle M. Picarello, Christine Pulizos, Laura Ramirez, A. Renton, J. Ringman, Jacqueline Rizzo, Yvonne Roedenbeck, P. Rosa-Neto, Edita Sabaredzovic, S. Salloway, R. Sánchez-Valle, Jalen Scott, Nicholas T. Seyfried, A. Simmons, Jennifer Smith, H. Smith, Jennifer Stauber, Sarah Stout, C. Supnet‐Bell, E. Surace, Silvia Vazquez, Jonathan Vöglein, Guoqiao Wang, Qing Wang, Chengie Xiong, Xiong Xu, Jinbin Xu

Open Access
24 citations
Analysis v6

Related Content

Claims (6)

Assertion

Blood levels of neurofilament light chain rise 9 to 10 years before a person is diagnosed with Alzheimer's disease, indicating that nerve cell damage is already occurring.

Descriptive
Read analysis
Assertion

In people with inherited Alzheimer’s disease, levels of neurofilament light chain in cerebrospinal fluid and blood increase together 10 to 20 years before symptoms appear and both correlate with loss of brain gray matter. After symptoms begin, blood levels stabilize but cerebrospinal fluid levels keep rising, showing that cerebrospinal fluid neurofilament light chain more accurately reflects ongoing nerve cell damage during the symptomatic phase.

Mechanistic
Read analysis
Assertion

In people with inherited Alzheimer’s disease, levels of neurofilament light chain in spinal fluid and blood are closely linked before symptoms appear, but this link becomes much weaker after symptoms start, meaning blood levels are less accurate for tracking brain degeneration once the disease is active.

Correlational
Read analysis
Assertion

In people with inherited Alzheimer’s disease, higher levels of neurofilament light chain in spinal fluid and blood correlate with faster loss of brain tissue during symptom onset, but not with the amount of amyloid-beta protein buildup.

Correlational
Read analysis
Assertion

In people with inherited Alzheimer’s disease, levels of neurofilament light chain in cerebrospinal fluid rise about 24.6 years before symptoms appear, while levels in plasma rise about 18.9 years before symptoms, showing that cerebrospinal fluid levels increase earlier than plasma levels.

Descriptive
Read analysis
Assertion

In people with inherited Alzheimer’s disease, the ratio of neurofilament light chain in blood versus spinal fluid drops significantly when symptoms appear, reflecting a change in how this protein moves from the brain into the bloodstream.

Mechanistic
Read analysis
Fit Body Science verdict — we translate health studies into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.